Skip to main content

MoneyWorks4Me

Wanbury informs about press release

20 Nov 2026 Evaluate

Pursuant to Regulation 30 of SEBI LODR, Wanbury has informed that company’s API manufacturing facility at Tanuku, Andhra Pradesh, has successfully completed a three-day cGMP inspection conducted by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, with zero observations. The inspection was conducted by two senior inspectors from South Korea’s MFDS, a leading international pharmaceutical regulatory authority, covering the facility’s compliance with applicable Good Manufacturing Practices (cGMP) standards. This achievement follows the successful completion of a South Korea MFDS cGMP inspection at the Company’s Patalganga manufacturing facility in April 2026, which was also concluded with zero observations. These consecutive achievements reflect Wanbury Limited’s strong commitment to quality, regulatory compliance and operational excellence. The Company remains focused on continuously strengthening its quality systems and enhancing manufacturing standards in line with evolving international regulatory requirements and global cGMP expectations. 

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1885.10
Dr. Reddys Labs. 1390.50
Cipla 1414.95
Lupin 2010.00
Zydus Lifesciences 1195.05
View more..